Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled time : 13:20 save search
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
NVCR | $12.03 -0.17% 140K
|
Health Technology
|
| O: -0.75%
H: 2.79%
C: 1.59%
favorable cancer pancreatic tumor trial therapy
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
Published: 2023-06-01 (Crawled : 13:20) - biospace.com/
GILD | News | $66.495 0.51% 1.9M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -1.72%
pipeline cell growing therapy
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
Published: 2023-05-24 (Crawled : 13:20) - globenewswire.com
CLPT | $5.37 -0.37% 10K
|
Health Technology
|
| O: -1.46%
H: 2.59%
C: -2.35%
drug license agreement therapy
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Published: 2023-05-19 (Crawled : 13:20) - globenewswire.com
CADL | $5.425 -0.64% 160K
|
|
| O: 0.63%
H: 0.0%
C: -8.72%
can-3110 cell ongoing meeting trial therapeutics therapy
Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration
Published: 2023-05-03 (Crawled : 13:20) - biospace.com/
LH M | $200.03 0.29% 130K
|
Health Services
|
| O: 0.89%
H: 0.66%
C: -0.87%
collaboration therapy
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
Published: 2023-04-27 (Crawled : 13:20) - biospace.com/
LLY | $731.1 -1.99% 1M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
NKTR | $1.275 -3.41% 270K
|
Health Technology
|
| O: 0.26%
H: 1.82%
C: -2.21%
nktr-358 t-cell therapeutics therapy
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting
Published: 2023-04-19 (Crawled : 13:20) - prnewswire.com
GNPX | $2.2194 12K
|
Health Technology
|
| O: 15.79%
H: 0.0%
C: -10.0%
oncoprex lung report positive cancer cell system preclinical meeting therapy
REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
RGNX | $15.925 -1.15% 120K
|
Health Technology
|
| O: 1.68%
H: 3.7%
C: 0.91%
rgx-202 fda candidate treatment designation duchenne therapy fast track designation
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Published: 2023-03-23 (Crawled : 13:20) - prnewswire.com
NRSN | News | $1.52 27K
|
|
| O: 0.0%
H: 4.85%
C: 0.61%
conference disease als alzheimer's therapy
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
Published: 2023-02-17 (Crawled : 13:20) - globenewswire.com
JSPR | $23.13 -0.35% 8.1K
|
|
| O: 3.83%
H: 0.53%
C: -4.21%
ongoing cibmtr therapeutics therapy
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
Published: 2023-02-17 (Crawled : 13:20) - globenewswire.com
JSPR | $23.13 -0.35% 8.1K
|
|
| O: 3.83%
H: 0.53%
C: -4.21%
cibmtr anemia therapeutics positive therapy study
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Published: 2023-02-16 (Crawled : 13:20) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.19%
H: 0.36%
C: -0.52%
plus therapy cancer prostate cancer
Scripps Health Radiation Therapy Centers Named Patient Safety Center of Excellence by Sun Nuclear
Published: 2023-01-26 (Crawled : 13:20) - prnewswire.com
MIR | $10.965 1.53% 380K
|
|
| O: 1.29%
H: 1.28%
C: 0.64%
LEA | News | $132.3 0.87% 35K
|
Producer Manufacturing
|
| O: 1.48%
H: 0.25%
C: -0.34%
health nuclear therapy
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Published: 2023-01-24 (Crawled : 13:20) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -0.15%
H: 18.49%
C: 15.32%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.15%
H: 0.18%
C: -0.48%
candidate application trial approval therapeutics therapy
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
Published: 2023-01-19 (Crawled : 13:20) - globenewswire.com
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 3.29%
H: 3.55%
C: -9.07%
flt190 candidate preclinical therapy
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
Published: 2023-01-18 (Crawled : 13:20) - renovorx.com
RNXT | $1.22 9.5K
|
|
| O: 1.27%
H: 25.0%
C: -8.75%
renovotamp treatment potential gemcitabine therapy cancer platform pancreatic
Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published: 2023-01-13 (Crawled : 13:20) - globenewswire.com
JSPR | $23.13 -0.35% 8.1K
|
|
| O: 23.64%
H: 39.71%
C: -12.75%
cibmtr therapeutics positive therapy
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Published: 2023-01-06 (Crawled : 13:20) - globenewswire.com
CELU | News F | $3.21 7.7K
|
|
| O: 0.3%
H: 3.79%
C: -2.23%
disease therapy phase 2b
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
GILD | News | $66.495 0.51% 1.9M
|
Health Technology
|
| O: -3.21%
H: 1.93%
C: 1.35%
acquire t-cell therapeutics therapy cancer
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular EdemaRZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
RZLT 4 | $3.385 2.58% 130K
|
Technology Services
|
| O: 0.66%
H: 2.61%
C: -2.61%
rz402 macular eye alternative potential therapy study diabetic
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.3022 24.82% 51M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.